Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107629 | 0.92 | PTGDR2 (0.46) | PTGDR2MAPTNPSR1LMNAL3MBTL1 | |
| SCHEMBL5121570 | 0.88 | KMT2A (0.43) | PTGDR2MAPTNPSR1LMNAL3MBTL1 | |
| SCHEMBL5122186 | 0.88 | NPSR1 (0.44) | PTGDR2MAPTNPSR1LMNAL3MBTL1 | |
| SCHEMBL5107864 | 0.86 | NPSR1 (0.43) | PTGDR2MAPTNPSR1LMNAL3MBTL1 | |
| SCHEMBL5121197 | 0.86 | PTGDR2 (0.40) | PTGDR2MAPTNPSR1LMNA | |
| SCHEMBL5107880 | 0.85 | PTGDR2 (0.44) | PTGDR2MAPTNPSR1LMNAL3MBTL1 | |
| SCHEMBL5108429 | 0.84 | PTGDR2 (0.41) | PTGDR2MAPTNPSR1LMNAL3MBTL1 | |
| SCHEMBL5114030 | 0.84 | PTGDR2 (0.38) | PTGDR2MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL5120798 | 0.83 | PTGDR2 (0.59) | PTGDR2MAPTNPSR1LMNAL3MBTL1 | |
| SCHEMBL5121162 | 0.83 | PTGDR2 (0.64) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273740-B2 | antiallergen; not direct way to change nature of immunological response to allergen; G-protein-coupled \"chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)\" antagonist for prostaglandin PGD2, that mediates PGD2-dependent migration of blood Th2 cells; ; asthma, rhinitis, COPD | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | ACTELION PHARMACEUTICALS,LTD. (CH) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | HRH2, HRH1, HRH3 | PTGDR2 12/4885MAPT 4293/4885NPSR1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.